A detailed history of Captrust Financial Advisors transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 15,820 shares of VIR stock, worth $116,751. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,820
Holding current value
$116,751
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.26 - $10.7 $114,853 - $169,274
15,820 New
15,820 $118,000
Q2 2022

Aug 16, 2022

BUY
$19.08 - $26.7 $32,245 - $45,123
1,690 Added 1270.68%
1,823 $46,000
Q1 2022

May 16, 2022

SELL
$21.19 - $40.01 $63 - $120
-3 Reduced 2.21%
133 $3,000
Q4 2021

Feb 14, 2022

BUY
$30.97 - $54.03 $4,211 - $7,348
136 New
136 $6,000
Q1 2021

May 17, 2021

SELL
$26.34 - $83.07 $13,170 - $41,535
-500 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$25.51 - $43.38 $12,755 - $21,690
500 New
500 $13,000

Others Institutions Holding VIR

About Vir Biotechnology, Inc.


  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $979M
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.